Citadel Advisors
HEPA

Citadel Advisors’s Hepion Pharmaceuticals HEPA Stock Holding History

Citadel Advisors’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35
Closed -$27K – 14706
2023
Q1 		$27K Buy
35
+4
+13% +$2.96K ﹤0.01% 12827
2022
Q4 		$9.15K Sell
31
-17
-35% -$7.18K ﹤0.01% 13702
2022
Q3 		$24K Buy
48
+3
+7% +$1.83K ﹤0.01% 12001
2022
Q2 		$26K Sell
45
-22
-33% -$18.3K ﹤0.01% 12294
2022
Q1 		$87K Buy
67
+18
+37% +$19.9K ﹤0.01% 12409
2021
Q4 		$55K Buy
49
+21
+75% +$28.8K ﹤0.01% 13192
2021
Q3 		$42K Sell
28
-77
-73% -$123K ﹤0.01% 13455
2021
Q2 		$208K Buy
105
+26
+33% +$47.6K ﹤0.01% 12068
2021
Q1 		$145K Buy
79
+32
+68% +$70.2K ﹤0.01% 12087
2020
Q4 		$102K Buy
47
+19
+68% +$49.2K ﹤0.01% 10208
2020
Q3 		$88K Buy
+28
New +$100K ﹤0.01% 9347

Other funds holding HEPA

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's HEPA Position: Q2 2025 in Review

Citadel Advisors sold out of Hepion Pharmaceuticals (HEPA) in Q2 2025, closing a stake of 15,581 shares — an estimated $6.7K sold.

Citadel Advisors first reported a position in HEPA in Q4 2018 and held it in 13 quarters. The position peaked at $114K in Q2 2021. 4 funds tracked by Wall St. Rank hold HEPA as of Q2 2025.

  • Citadel Advisors reported no remaining Hepion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 15,581 Hepion Pharmaceuticals shares in Q2 2025, an estimated $6.7K.
  • Citadel Advisors first reported a position in Hepion Pharmaceuticals in Q4 2018 and held it in 13 quarters.
  • Citadel Advisors's Hepion Pharmaceuticals position peaked at $114K in Q2 2021.
  • 4 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.